UBS analyst AJ Rice lowered the firm’s price target on Elevance Health (ELV) to $484 from $555 and keeps a Buy rating on the shares. Elevance is the only managed care organization with government exposure showing meaningful positive EPS growth, and questions remain around whether the company will need to revise earnings, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025
- Elevance Health price target lowered to $447 from $518 at Guggenheim
- Elevance Health price target lowered to $434 from $480 at Barclays
- Molina Healthcare price target lowered to $248 from $309 at BofA
- Pressure continues to mount on health insurers as costs rise, WSJ says